Herantis Pharma Oyj Logo

Herantis Pharma Oyj

Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.

HRTIS | ST

Overview

Corporate Details

ISIN(s):
FI4000087861
LEI:
743700W4CQVYAT3WKK38
Country:
Finland
Address:
Bertel Jungin Aukio 1, FI-02600 ESPOO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Herantis Pharma is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative conditions, with a primary emphasis on Parkinson's disease. The company's mission is to address significant unmet medical needs by creating treatments designed to stop or reverse disease progression. Its research and development efforts are centered on its proprietary technology platform, which includes lead drug candidates like HER-096, a therapy based on the Cerebral Dopamine Neurotrophic Factor (CDNF) protein.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Herantis Pharma Oyj filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Herantis Pharma Oyj

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Herantis Pharma Oyj via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.